New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
06:22 EDTINCYIncyte price target raised to $75 from $44 at Jefferies
Jefferies raised its price target for Incyte shares to $75 from $44 on expectations the company's IDO inhibitor with ipilimumab for melanoma could "unlock huge value." The firm says it heard positive commentary from four investigators involved in the Phase 2 study and keeps a Buy rating on the stock.
News For INCY From The Last 14 Days
Check below for free stories on INCY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2014
13:39 EDTINCYIncyte reported strong Q2 results, says Leerink
Subscribe for More Information
13:18 EDTINCYIncyte shares defended at UBS
Subscribe for More Information
12:52 EDTINCYIncyte weakness a buying opportunity, says Brean Capital
Subscribe for More Information
07:22 EDTINCYIncyte raises FY14 Jakafi net product revenue view to $330M-$340M
Subscribe for More Information
07:15 EDTINCYIncyte reports Q2 EPS (22c), may not compare to consensus (4c)
Reports Q2 revenue $99.6M, consensus $127.19M.
July 30, 2014
08:32 EDTINCYIncyte announces clinical trial agreement with Genentech
Subscribe for More Information
July 28, 2014
07:02 EDTINCYIncyte says FDA approves supplemental labeling for Jakafi
Subscribe for More Information
July 24, 2014
06:57 EDTINCYIncyte trial miss does not impact Jakafi assumptions, says Leerink
Subscribe for More Information
July 23, 2014
16:41 EDTINCYIncyte's Ruxolitinib shows no statistical significance in primary endpoint
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use